13F Holdings
中文EN

EVAX Evaxion A/S IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1828253 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY125.1%
TTM net income YoY27.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-122.7%
Net margin-102.4%
FCF margin-88.2%
EBITDA margin—

Returns

ROE-100.2%
ROA-37.7%
ROIC (approx.)—
Asset turnover0.37x

Leverage & solvency

Liabilities / assets40.0%
Debt / equity0.32x
Current ratio5.85x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$7.53M$3.34M$73,000$0—
R&D expense$9.97M$10.46M$11.92M$17.06M$19.58M
SG&A expense$6.79M$7.62M$10.35M$8.21M$6.25M
Operating income-$9.23M-$14.73M-$22.20M-$25.26M-$25.83M
Interest expense$0$0$1,000$34,000$5,000
Pretax income-$8.62M-$11.36M-$22.91M-$23.94M-$24.71M
Income tax-$908,000-$788,000-$790,000-$772,000-$178,000
Net income-$7.71M-$10.57M-$22.12M-$23.17M-$24.53M
EPS (basic)-0.02-0.20-0.81-0.98-1.26
EPS (diluted)——-0.81-0.98-1.26
Balance sheet
Cash & equivalents$23.23M$5.95M$5.58M$13.18M$32.17M
Receivables——$1.95M$2.79M$1.14M
Current assets$24.90M$8.77M$8.35M$16.98M$34.70M
PP&E, netmay include right-of-use assets (IFRS)$3.32M$3.51M$4.34M$4.67M$5.17M
Intangibles$0$0$0—$93,000
Total assets$28.41M$12.48M$12.89M$22.02M$40.16M
Current liabilities$4.26M$4.37M$7.08M$3.76M$4.32M
Short-term debt$190,000$159,000$159,000$136,000$126,000
Long-term debt$5.35M$8.01M$8.49M$7.86M$1.04M
Total debt$5.54M$8.17M$8.65M$8.00M$1.17M
Total liabilities$11.37M$14.14M$17.62M$13.72M$7.73M
Shareholders' equity$17.04M-$1.65M-$4.73M$8.30M$32.44M
Net debt-$17.70M$2.21M$3.06M-$5.18M-$31.00M
Shares outstanding417.01M————
Cash flow statement
Operating cash flow-$6.62M-$12.94M-$17.69M-$25.77M-$21.93M
Capital expenditure$11,000$0$87,000$292,000$1.30M
Free cash flow-$6.64M-$12.94M-$17.78M-$26.07M-$23.23M
Investing cash flow-$14,000-$3,000-$93,000-$268,000-$1.33M
Financing cash flow$22.41M$13.13M$10.69M$7.85M$49.80M
Stock-based compensation$307,000$357,000$479,000$942,000$1.38M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.